• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of 5-Fluoro-2-methylpyridine-4-carboxylic Acid (CAS: 885588-17-0) in Chemical Biology and Pharmaceutical Research

The compound 5-fluoro-2-methylpyridine-4-carboxylic acid (CAS: 885588-17-0) has recently emerged as a key intermediate in the synthesis of novel pharmaceutical agents, particularly in the development of kinase inhibitors and antimicrobial compounds. This heterocyclic carboxylic acid derivative exhibits unique structural features that make it a versatile building block for drug discovery. Recent studies have highlighted its role in modulating biological targets through strategic fluorination and carboxyl group interactions, offering new avenues for therapeutic intervention.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in creating potent FGFR (fibroblast growth factor receptor) inhibitors. Researchers incorporated 5-fluoro-2-methylpyridine-4-carboxylic acid as a core scaffold, achieving significant improvements in binding affinity (IC50 values in the low nanomolar range) and selectivity profiles. The fluorine atom at the 5-position was found to enhance metabolic stability while the carboxyl group facilitated critical hydrogen bonding interactions with the kinase's hinge region.

In antimicrobial applications, a team from the University of Manchester reported in Bioorganic & Medicinal Chemistry Letters (2024) that derivatives of 885588-17-0 showed promising activity against drug-resistant Staphylococcus aureus strains. The electron-withdrawing effect of the fluorine atom appears to enhance membrane penetration, while the carboxylic acid moiety contributes to target engagement with bacterial topoisomerase IV. These findings suggest potential for developing new antibiotics addressing the growing antimicrobial resistance crisis.

The synthetic accessibility of 5-fluoro-2-methylpyridine-4-carboxylic acid has also been improved through recent methodological advances. A 2024 Nature Protocols paper detailed an optimized continuous-flow synthesis route that achieves 85% yield with excellent purity (>99%), addressing previous challenges in large-scale production. This development is particularly significant for pharmaceutical companies looking to incorporate this building block into their drug discovery pipelines.

Structural-activity relationship (SAR) studies have revealed that the spatial arrangement of the fluorine and carboxylic acid groups in 885588-17-0 creates an optimal pharmacophore for several target classes. Computational modeling indicates this configuration allows for simultaneous hydrophobic (through the methyl group) and electrostatic (through the carboxylate) interactions with protein binding pockets. These insights are guiding the design of next-generation small molecule therapeutics across multiple disease areas.

Ongoing clinical trials featuring compounds derived from 5-fluoro-2-methylpyridine-4-carboxylic acid include Phase II studies for non-small cell lung cancer (NSCLC) and inflammatory bowel disease. Preliminary results suggest favorable pharmacokinetic profiles, with the fluorine atom contributing to extended half-lives and the carboxylic acid enabling dose-dependent exposure. These developments position 885588-17-0 as an increasingly important structural motif in medicinal chemistry.

Future research directions for this compound include exploration of its potential in PROTAC (proteolysis targeting chimera) design and as a linker in antibody-drug conjugates. The bifunctional nature of the molecule - capable of both hydrogen bond donation/acceptance and participating in click chemistry reactions - makes it particularly attractive for these emerging therapeutic modalities. Several biotech companies have already filed patent applications covering novel uses of this scaffold in targeted protein degradation platforms.

• 86053-13-6(6-Fluoro-2-methylquinoline-5-carboxylic acid)
• 1214355-06-2(5-Fluoro-2-(2-fluorophenyl)isonicotinic acid)
• 1260784-53-9(Ethyl 3-fluoro-2-methylisonicotinate)
• 1379375-22-0(2-(Difluoromethyl)-3-fluoroisonicotinic acid)
• 393-53-3(3-fluoropyridine-4-carboxylic acid)
• 1214391-49-7(5-Fluoro-2-(3-fluorophenyl)isonicotinic acid)
• 885588-15-8(methyl 5-fluoro-2-methyl-pyridine-4-carboxylate)
• 903522-29-2(3,5-Difluoroisonicotinic acid)
• 885588-18-1(4-Pyridinecarboxylic acid, 5-fluoro-2-phenyl-)
• 1427082-33-4(5-fluoropyridine-2,4-dicarboxylic acid)